{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:56:37Z","timestamp":1789059397035,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rett syndrome (RTT) is an uncommon inherited neurodevelopmental disorder that affects brain development, mostly in females. It results from mutation in MECP2 gene in the long arm (q) of the X chromosome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Trofinetide is a recently developed drug that has a neuroprotective effect on neurons, and it is our aim in this meta-analysis to evaluate its efficacy and safety in treating Rett syndrome patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched 5 databases (PubMed, Scopus, Embase, Web of Science, and Cochrane Library databases) to identify randomized controlled trials (RCTs) comparing Trofinetide and placebo in patients with Rett syndrome until August 13, 2023.Our primary outcomes were the Clinical Global Impression-Improvement (CGI) and the Rett syndrome Behavior Questionnaire (RSBQ). We used Risk of Bias Assessment tool-2 (ROB2) to assess the methodological quality of the included randomized controlled trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three RCTs with a total of 325 patients were included with a follow-up duration ranging from one month to three months. 186 patients received the intervention drug (Trofinetide) and 138 received the placebo. Trofinetide was found to reduce CGI and RSBQ significantly more than placebo (MD\u2009=\u2009-0.35, 95% CI [-0.52 to -0.18], P 0.0001), (MD\u2009=\u2009-3.40, 95% CI [-3.69 to -3.12], P 0.00001) respectively. Most adverse events did not show any statistical difference between Trofinetide and the placebo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Trofinetide offers promise as a potential effective and safe therapeutic opportunity for a population without many available treatments, with improvements seen on both CGI and RSBQ assessments and no severe adverse effects reported.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-024-07584-8","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:04:16Z","timestamp":1716303856000},"page":"4767-4778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A meta-analysis of the efficacy and safety of trofinetide in patients with rett syndrome"],"prefix":"10.1007","volume":"45","author":[{"given":"Mohamed","family":"Abo Zeid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Elrosasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashad G.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Ghazou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elarbi","family":"Goufa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Abuzaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"issue":"2","key":"7584_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1021\/acschemneuro.7b00346","volume":"9","author":"WA Gold","year":"2018","unstructured":"Gold WA, Krishnarajy R, Ellaway C, Christodoulou J (2018) Rett Syndrome: A Genetic Update and Clinical Review Focusing on Comorbidities. ACS Chem Neurosci 9(2):167\u2013176. https:\/\/doi.org\/10.1021\/acschemneuro.7b00346","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"7584_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/13810","volume":"23","author":"RE Amir","year":"1999","unstructured":"Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23(2):185\u2013188. https:\/\/doi.org\/10.1038\/13810","journal-title":"Nat Genet"},{"issue":"16","key":"7584_CR3","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.3390\/ijms20163925","volume":"20","author":"S Vidal","year":"2019","unstructured":"Vidal S, Xiol C, Pascual-Alonso A, O\u2019Callaghan M, Pineda M, Armstrong J (2019) Genetic Landscape of Rett Syndrome Spectrum: Improvements and Challenges. Int J Mol Sci 20(16):3925. https:\/\/doi.org\/10.3390\/ijms20163925","journal-title":"Int J Mol Sci"},{"key":"7584_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/6154080","volume":"2016","author":"D Feldman","year":"2016","unstructured":"Feldman D, Banerjee A, Sur M (2016) Developmental Dynamics of Rett Syndrome. Neural Plast 2016:1\u20139. https:\/\/doi.org\/10.1155\/2016\/6154080","journal-title":"Neural Plast"},{"issue":"2","key":"7584_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12017-014-8296-8","volume":"16","author":"VRB Liyanage","year":"2014","unstructured":"Liyanage VRB, Rastegar M (2014) Rett Syndrome and MeCP2. Neuromolecular Med 16(2):231\u2013264. https:\/\/doi.org\/10.1007\/s12017-014-8296-8","journal-title":"Neuromolecular Med"},{"issue":"1","key":"7584_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13073-017-0407-5","volume":"9","author":"RR Shah","year":"2017","unstructured":"Shah RR, Bird AP (2017) MeCP2 mutations: progress towards understanding and treating Rett syndrome. Genome Med 9(1):17. https:\/\/doi.org\/10.1186\/s13073-017-0407-5","journal-title":"Genome Med"},{"issue":"2","key":"7584_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/mrdd.10029","volume":"8","author":"B Hagberg","year":"2002","unstructured":"Hagberg B (2002) Clinical manifestations and stages of rett syndrome. Ment Retard Dev Disabil Res Rev 8(2):61\u201365. https:\/\/doi.org\/10.1002\/mrdd.10029","journal-title":"Ment Retard Dev Disabil Res Rev"},{"issue":"S1","key":"7584_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/ajmg.1320250507","volume":"25","author":"B Hagberg","year":"1986","unstructured":"Hagberg B, Witt-Engerstr\u00f6m I, Opitz JM, Reynolds JF (1986) Rett Syndrome: A suggested staging system for describing impairment profile with increasing age towards adolescence. Am J Med Genet 25(S1):47\u201359. https:\/\/doi.org\/10.1002\/ajmg.1320250507","journal-title":"Am J Med Genet"},{"issue":"6","key":"7584_CR9","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/ana.22124","volume":"68","author":"JL Neul","year":"2010","unstructured":"Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N et al (2010) Rett syndrome: Revised diagnostic criteria and nomenclature. Ann Neurol 68(6):944\u2013950. https:\/\/doi.org\/10.1002\/ana.22124","journal-title":"Ann Neurol"},{"key":"7584_CR10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.neubiorev.2019.01.016","volume":"98","author":"C Einspieler","year":"2019","unstructured":"Einspieler C, Marschik PB (2019) Regression in Rett syndrome: Developmental pathways to its onset. Neurosci Biobehav Rev 98:320\u2013332. https:\/\/doi.org\/10.1016\/j.neubiorev.2019.01.016","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"7584_CR11","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.ridd.2013.01.002","volume":"34","author":"PB Marschik","year":"2013","unstructured":"Marschik PB, Kaufmann WE, Sigafoos J, Wolin T, Zhang D, Bartl-Pokorny KD et al (2013) Changing the perspective on early development of Rett syndrome. Res Dev Disabil 34(4):1236\u20131239. https:\/\/doi.org\/10.1016\/j.ridd.2013.01.002","journal-title":"Res Dev Disabil"},{"issue":"7","key":"7584_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/brainsci10070410","volume":"10","author":"M Fonzo","year":"2020","unstructured":"Fonzo M, Sirico F, Corrado B (2020) Evidence-Based Physical Therapy for Individuals with Rett Syndrome: A Systematic Review. Brain Sci 10(7):410. https:\/\/doi.org\/10.3390\/brainsci10070410","journal-title":"Brain Sci"},{"issue":"6","key":"7584_CR13","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1073\/pnas.0812394106","volume":"106","author":"D Tropea","year":"2009","unstructured":"Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD et al (2009) Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci 106(6):2029\u20132034. https:\/\/doi.org\/10.1073\/pnas.0812394106","journal-title":"Proc Natl Acad Sci"},{"key":"7584_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol 134:103\u2013112. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.02.003","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"7584_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"7584_CR16","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 28:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"7584_CR17","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2023) Cochrane handbook for systematic reviews of interventions version 6.4. Cochrane. Available from www.training.cochrane.org\/handbook"},{"key":"7584_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","volume":"76","author":"DG Glaze","year":"2017","unstructured":"Glaze DG, JeffreyL Neul, Percy A, Feyma T, Beisang A, Yaroshinsky A et al (2017) A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome. Pediatr Neurol 76:37\u201346. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.07.002","journal-title":"Pediatr Neurol"},{"issue":"16","key":"7584_CR19","doi-asserted-by":"publisher","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","volume":"92","author":"DG Glaze","year":"2019","unstructured":"Glaze DG, Neul JL, Kaufmann WE, Berry-Kravis E, Condon S, Stoms G et al (2019) Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology 92(16):e1912\u2013e1925. https:\/\/doi.org\/10.1212\/WNL.0000000000007316","journal-title":"Neurology"},{"issue":"6","key":"7584_CR20","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","volume":"29","author":"JL Neul","year":"2023","unstructured":"Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Marsh ED et al (2023) Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. Nat Med 29(6):1468\u20131475. https:\/\/doi.org\/10.1038\/s41591-023-02398-1","journal-title":"Nat Med"},{"key":"7584_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.pediatrneurol.2020.01.009","volume":"107","author":"W Hou","year":"2020","unstructured":"Hou W, Bhattacharya U, Pradana WA, Tarquinio DC (2020) Assessment of a Clinical Trial Metric for Rett Syndrome: Critical Analysis of the Rett Syndrome Behavioural Questionnaire. Pediatr Neurol 107:48\u201356. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2020.01.009","journal-title":"Pediatr Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07584-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07584-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07584-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:25:27Z","timestamp":1727184327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07584-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["7584"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07584-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"14 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}